# HIP1

Source: https://onco.cc/targets/hip1/  
OnCo record `hip1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HIP1 (Huntingtin-interacting protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Lung cancer and 3 more.

## Summary

Plays a role in clathrin-mediated endocytosis and trafficking. Involved in regulating AMPA receptor trafficking in the central nervous system in an NMDA-dependent manner. Regulates presynaptic nerve terminal activity.

Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes affected pathway 0.83, literature 0.86, genetic association 0.00, somatic mutation 0.83, animal model 0.62). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Medulloblastoma, Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumour, Upper Tract Urothelial Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: huntingtin interacting protein 1; Huntingtin-interacting protein 1; ILWEQ
- Tags: cancer-genes-wave
- Symbol: HIP1
- Class: transcription
- Biology: Plays a role in clathrin-mediated endocytosis and trafficking. Involved in regulating AMPA receptor trafficking in the central nervous system in an NMDA-dependent manner. Regulates presynaptic nerve terminal activity. Enhances androgen receptor (AR)-mediated transcription. May act as a proapoptotic protein that induces cell death by acting through the intrinsic apoptosis pathway. Binds 3-phosphoinositides (via ENTH domain). Location: Cytoplasm; Nucleus; Endomembrane system; Cytoplasmic vesicle, clathrin-coated vesicle membrane (UniProt). Locus 7q11.23 (HGNC).
- Where found: Bladder & urothelial cancer: IntOGen driver in 1 cohort (UTUC); Breast cancer: Open Targets association 0.56 with breast cancer (MONDO_0007254); Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903); Skin cancer: Open Targets association 0.50 with skin cancer (MONDO_0002898); Medulloblastoma: IntOGen driver in 1 cohort (MBL); Uterine carcinosarcoma: IntOGen driver in 1 cohort (UCS)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:4913: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4913
- UniProt O00291: https://www.uniprot.org/uniprotkb/O00291/entry
- NCBI Gene 3092: https://www.ncbi.nlm.nih.gov/gene/3092
- Ensembl ENSG00000127946: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000127946

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Uterine carcinosarcoma](https://onco.cc/cancers/uterine-carcinosarcoma/)

---
JSON: https://onco.cc/api/v1/entities/hip1.json